BRIEF-CSL And Lilly Enter Licensing Agreement For Clazakizumab
Eli Lilly and Company -2.60%
Carlisle Companies Incorporated -1.83%
Eli Lilly and Company LLY | 898.53 | -2.60% |
Carlisle Companies Incorporated CSL | 351.15 | -1.83% |
Feb 18 (Reuters) - CSL Ltd CSL.AX:
CSL AND LILLY ENTER LICENSING AGREEMENT FOR CLAZAKIZUMAB
EXCLUSIVE LICENSING AGREEMENT GRANTING CERTAIN RIGHTS TO DEVELOP AND COMMERCIALISE CLAZAKIZUMAB
CSL WILL RECEIVE AN UPFRONT PAYMENT OF $100 MILLION
CSL WILL RETAIN EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALISE CLAZAKIZUMAB FOR PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH END-STAGE KIDNEY DISEASE
Further company coverage: CSL.AX
